Analysis of the clinical course of patients with type 2 diabetes mellitus from onset of insulin treatment (EDIN study): baseline characteristics of patients
Angel Rodríguez, Elena Caveda & Jesús Reviriego
Introduction: The EDIN study evaluated the clinical course of patients with type 2 diabetes mellitus (T2DM) from the start of the insulin treatment to a minimum of 5 years, within routine clinical practice in Spain.
Objective: To describe the characteristics of patients at onset of insulin treatment.
Methods: Observational study that consecutively included patients with T2DM, ≥30 years old and treated with insulin for at least 5 years. Data were collected retrospectively in 2008 from patients clinical records.
Results: Fifty-three sites participated in the study. A total of 405 patients were enrolled and 377 were included in the analysis (52.0% males; mean age (S.D.) 65 (9.1) years; mean body mass index (S.D.) 29.9 (4.7) kg/m2). Mean time from onset of T2DM (S.D.) was 8.8 (6.9) years. Almost two-thirds of the patients had family history of T2DM. Insulin treatment pattern showed that 48% of the patients were prescribed human basal insulin and 29.4% were treated with premix human insulin. Three hundred sixty patients (95.5%) were being treated with oral antidiabetic medications. Collection of cardiovascular risk factors showed that ≥50% of the patients presented overweight (75.1%), hypertension (50.4%) and dyslipidemia (59.2%); however, 60.2% of the patients were non-smokers. Microvascular complications were identified in 121 (32.1%) patients and the most frequent conditions were diabetic retinopathy (n=92, 76.0%), diabetic nephropathy (n=46, 38.0%) and diabetic neuropathy (n=41, 33.9%). Macrovascular complications were present in 66 patients (17.5%), among which coronary artery disease (n=38, 57.6%) and cardiovascular disease (n=28, 42.2%) were the most common conditions.
Conclusion: Patient characteristics at onset of insulin treatment showed family history of T2DM, high presence of cardiovascular risk factors and micro/macrovascular complications. Most of the patients were prescribed human basal insulin or premix human insulin, showing treatment pattern in routine clinical practice in Spain at that moment.